OptimizeRx (OPRX) risk factors, FY2025 10-K

Risks Related to Our Financial Position

1. 01We have a history of losses, and may not be able to achieve profitability, or, if achieved, sustain profitability22% rewritten
2. 02We may need to raise additional capital to grow our business and may not be able to do so on favorable terms, if at all47% rewritten
3. 03Servicing debt and funding other obligations requires a significant amount of cash, and our ability to generate sufficient cash depends on many factors, some of which are beyond our control
4. 04Restrictions in our Term Loan could adversely affect our business, financial condition, results of operations, ability to make distributions, and the value of our securities

Risks Related to Our Business: Our Industry, Operations, and Competition

1. 05Seasonal trends in the pharmaceutical brand marketing industry could affect our operating results31% rewritten
2. 06Developing and implementing new and updated applications, features and services for our solutions may be more difficult than expected, may take longer and cost more than expected and may not result in sufficient increases in revenue to justify the costs
3. 07Any failure to offer high-quality customer support for our solutions may adversely affect our relationships with our customers and harm our financial results
4. 08We are dependent on a concentrated group of customers, and the loss of one or more of any of the pharmaceutical brands that purchase our solutions could cause our revenue to declineNew
5. 09If we are unable to maintain our contracts with electronic prescribing platforms and electronic health record systems, our business will suffer33% rewritten
6. 10Our agreements with eRx and EHR channel partners could be subject to audit
7. 11If we fail to attract new customers or retain and expand existing customers, our business and future prospects may be materially and adversely impacted45% rewritten
8. 12We expect to face increasing competition in the markets for our solutionsNew
9. 13Most of our revenue is derived from pharmaceutical manufacturers and could be affected by changes affecting the broader healthcare industry, including decreased spending in the industry overall

Risks Related to Regulatory Matters

1. 14Actual or perceived failures to comply with applicable laws and regulations that affect the healthcare industry, including data protection, privacy and security, fraud and abuse laws, regulations, standards and other requirements could adversely affect our business, results of operations, and financial condition22% rewritten
2. 15The current Executive Branch administration and regulatory agencies have proposed, and may propose additional, policy changes that create uncertainty for our business, our customers' businesses and the industries in which we operate, including for example, implementing restrictions on pharmaceutical DTC marketing68% rewritten
3. 16If our customers’ drug prices are reduced as a result of MFN pricing initiatives or other similar regulations, our business could be adversely affectedNew
4. 17If our customers, partners, and third-party providers fail to comply with the extensive and changing landscape of legal and regulatory requirements affecting the pharmaceutical and healthcare industries, they could face increased costs and/or penalties, which could lead to us losing business

Risks Related to Our Intellectual Property and Technology

1. 18We are dependent, in part, on our intellectual property. If we are not able to protect our proprietary rights or if those rights are invalidated or circumvented, our business may be adversely affected
2. 19Cybersecurity incidents could disrupt business operations, result in the loss of critical and confidential information, and adversely impact our reputation and results of operations
3. 20We may be unable to support our technology to further scale our operations successfully
4. 21Our business will suffer if our network systems fail or become unavailable
5. 22The use of AI technology in our operations and IT infrastructure could improve internal processes, but could pose security risks and privacy risks; the use of AI technology also faces regulatory uncertainty and scrutiny given that AI technology is rapidly growing and evolvingNew
6. 23We are aware that generative AI tools may respond with inaccurate or fabricated information, introduce bias, or fail to provide traceability of source information92% rewritten
7. 24Dependence on AI systems or AI vendors means that any downtime or outages can disrupt business operations. Usage of our confidential data to train the AI models by us or our vendors could result in legal risk, especially if it involves customer data or our proprietary informationNew
8. 25If we are unable to manage growth, our operations could be adversely affected
9. 26We may not be able to identify suitable acquisition candidates, complete acquisitions or integrate acquisitions successfully
10. 27Our acquisition activities may disrupt our ongoing business and may involve increased expenses, and we may not realize the financial and strategic goals contemplated at the time of a transaction

Risks Related to Inflation, Interest Rates, and Other Adverse Economic Conditions

1. 28Interest rate increases may adversely affect our financial condition and results of operations
2. 29We could be subject to economic, political, regulatory and other risks arising from our international operations
3. 30Inflation, the current interest rate environment, and other adverse economic conditions may adversely affect our business, results of operations and financial condition
4. 31Impairment charges for goodwill or other long-lived assets may need to be recognized, lose a major customer or experience changes to the regulatory environment affecting pharmaceutical advertising restricting the use of our technology39% rewritten
5. 32Market conditions could adversely change and our earnings could decline resulting in charges to impair intangible assets, such as goodwill51% rewritten
6. 33Geopolitical events may affect our business and our customer base and have a material adverse impact on our sales and operating results29% rewritten
7. 34Our business and growth may suffer if we are unable to attract and retain members of our senior management team and other key employees
8. 35The impact and effects of public health crises, pandemics and epidemics could have a material adverse effect on our business, prospects, financial condition, and operating results

Risks Relating to Our Common Stock

1. 36If a market for our common stock is not maintained, shareholders may be unable to sell their shares
2. 37The market price of our common stock may be highly volatile and could fluctuate widely in price in response to various factors, many of which are beyond our control40% rewritten
3. 38We do not expect to pay dividends in the foreseeable future and any return on investment may be limited to the value of our common stock
4. 39Certain provision of our articles of incorporation, bylaws and Nevada law may discourage takeover attempts and business combinations that shareholders might consider in their best interests
5. 40Actions of activist stockholders could be disruptive and costly and could adversely affect our results of operations, financial condition, and/or share price

Risks Related to Being a Public Company

1. 41We have identified a material weakness in our internal control over financial reporting. Failure to remediate the material weakness or any other material weaknesses that we identify in the future could result in material misstatements in our future financial statements
2. 42Conflicting views on environmental, social and governance matters may have a negative impact on our business, impose additional costs on us, and expose us to additional risks